Biocon to attend investor conferences on June 2 and June 8

Biocon has intimated the stock exchanges regarding its participation in upcoming investor conferences. The management is scheduled to meet analysts and institutional investors on two separate dates in June 2026.

The first meeting is scheduled for June 2, 2026, at the Morgan Stanley India Investment Forum 2026. This will be followed by a second engagement on June 8, 2026, at the ICICI Securities India Investor Conference 2026. Both events will take place in Mumbai and will feature one-on-one, group, and in-person interactions.

Schedule of Meetings

Date	Event	Type of Interaction	Venue
02-Jun-26	Morgan Stanley India Investment Forum 2026	1x1/Group/In-Person	Mumbai
08-Jun-26	ICICI Securities India Investor Conference 2026	1x1/Group/In-Person	Mumbai

The company clarified that the schedule is subject to change due to exigencies on the part of investors or the company. Furthermore, Biocon stated that it will not disclose any unpublished price sensitive information (UPSI) during these meetings.

The intimation was made pursuant to Regulation 30(6) of the SEBI Listing Regulations. The information is also available on the company's official website.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.14%	+2.68%	+19.02%	+8.42%	+26.30%	+12.48%

Biocon Pharma Limited, a subsidiary of Biocon Limited, announced on May 11, 2026, that it has received approval from Health Canada for micafungin for injection, USP, 50 mg and 100 mg. The development was disclosed to stock exchanges under Regulation 30 and marks a significant regulatory milestone for the company's generics business in Canada.

Approval Details

The Health Canada approval covers micafungin for injection in two strengths. The key details of the approved product are outlined below:

Parameter:	Details
Product Name:	Micafungin for Injection, USP
Strengths Approved:	50 mg and 100 mg
Regulatory Authority:	Health Canada
Approval Announcement Date:	May 11, 2026
Approving Entity:	Biocon Pharma Limited
Parent Company:	Biocon Limited

Indications and Patient Population

The approved product is indicated for use in adults and children four months and older. The approval encompasses the following therapeutic indications:

Treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections
Treatment of patients with esophageal candidiasis
Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation

Portfolio Strengthening

According to the company statement, this approval will further strengthen Biocon's integrated biosimilars and generics portfolio. The regulatory clearance from Health Canada represents an addition to the company's product offerings in the Canadian market. The announcement was made by Rajesh U. Shanoy, Company Secretary and Compliance Officer of Biocon Limited, and communicated to both BSE Limited and the National Stock Exchange of India Limited on May 11, 2026.